Abstract
In this review, a retinoid analogue (N-4-hydroxycarbophenyl) retinamide (R11) has been evaluated for its pharmacological and clinical properties. R11 has been studied both as a cancer prevention agent, as well as, a cancer chemotherapeutic agent. R11 alone and in combination with other agents can be used for the treatment of cervical dysplasia or leukemia. This review will examine novel strategies and mechanisms of action for retinoids in the treatment and prevention of cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Cell Differentiation / drug effects
-
Cricetinae
-
Drug Evaluation
-
Drug Screening Assays, Antitumor
-
Female
-
Free Radical Scavengers*
-
Gene Expression Regulation, Neoplastic / genetics
-
Humans
-
Leukoplakia / drug therapy*
-
Mice
-
Mouth Neoplasms / drug therapy*
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / prevention & control
-
Oncogenes
-
Proto-Oncogene Proteins c-fos / biosynthesis
-
Proto-Oncogene Proteins c-fos / genetics
-
Proto-Oncogene Proteins c-myc / biosynthesis
-
Proto-Oncogene Proteins c-myc / genetics
-
Rats
-
Structure-Activity Relationship
-
Tretinoin / analogs & derivatives*
-
Tretinoin / chemistry
-
Tretinoin / therapeutic use
-
Tumor Cells, Cultured / drug effects
-
Uterine Cervical Dysplasia / drug therapy*
-
Uterine Cervical Neoplasms / prevention & control*
Substances
-
Antineoplastic Agents
-
Free Radical Scavengers
-
Proto-Oncogene Proteins c-fos
-
Proto-Oncogene Proteins c-myc
-
Tretinoin
-
N-(4-carboxyphenyl)retinamide